Skip to main content

Table 1 Characteristics of eligible trials for general sarcoma with chemotherapy based treatment for phase I and phase II

From: Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Author Year Intervention No Osteo patients No Ewing Patients Phase Outcome
Pratt et al, Cancer, 74: 2593-8 [22] 1994 Leucovorin, 5-Fluorouracil 22 12 II Ewing: 3 (25%) SD, Osteo: 1 (5%) SD
Kushner et al, J Clin Oncol, 13 (11): 2796-804 [23] 1995 Cyclo, Doxo, Etop, Ifos, Vin Not mentioned Not mentioned II 6 (17%) CR, 2 (6%) PR, 34 (95%) CIR
Antman et al, Cancer, 82 (7): 1288-95 [24] 1998 Doxo, Dacarbazine, Ifos 31 13 II 10 (12%) CR, 34 (42%) PR
Blaney et al, Clin Cancer Res, 4 (2): 357-60 [25] 1998 Topotecan 18 25 II 1 (1%) CR, 1 (1%) PR, 8 (9%) SD
Lucidarme et al, Bone Marrow Transplant, 22 (6): 535-40 [26] 1998 Thiotepa combined with SCR 7 3 II 11 (50%) PR
Berg et al, J Pediatric Hematol Oncol, 22 (6): 506-9 [27] 2000 Pyrazoloacridine 8 10 II 0% response
Delaloge et al, J Clin Oncol, 19 (5): 1248-55 [28] 2001 Trabectedin 3 1 I 4 (14%) CR, 10 (35%) SD
Saylors et al, J Clin Oncol, 19 (15): 3463-9 [29] 2001 Cyclo and Topotecan 18 17 II 6 (35%) OR
Wagner et al, Clin Cancer Res, 10 (3): 840-8 [30] 2004 Temozolomide, Irinotecan 0 7 I 1 (8%) CR, 2 (17%) PR
Lau et al, Clin Cancer Res, 11: 672-7 [31] 2005 Trabectedin 4 3 I 1 (8%) CR
van Winkle et al, Pediatr Blood Cancer, 44 (4): 338-47 [32] 2005 Ifos, Carboplatin and Etop 35 22 I/II Not mentioned
Hawkins et al, Pediatr Blood Cancer, 47 (6): 328-37 [33] 2006 Topotecan 11 20 II 2 (4%) PR
Navid et al, Cancer, 106 (8): 1846-56 [34] 2006 Vin, Doxo, Cyclo, Ifos and Etop 0 11 II 47 (66%) CR
Wagner-Bohn et al, Cancer, 46 (2): 262 [35] 2006 Gemcitabine 2 4 II 2 (10%) SD
Zaucha et al, Int J Rad Oncol Biol Phys, 64 (1): 227-34 [36] 2006 Total body radiation after high-dose chemotherapy 0 10 II 13 (25%) CR, 10 (19%) PR
Zwerdling et al, Cancer, 106 (8): 1821-8 [37] 2006 Docetaxel 23 21 II 2 (1%) CR, 6 (3%) PR, 17 (10%) SD
Geoerger et al, J Clin Oncol, 26: 4394-400 [38] 2008 Oxaliplatin 6 2 I 2 (4%) PR, 17 (6%) SD
Geler et al, Pediatr Blood Cancer, 52 2009 Paclitaxel, Ifos 1 3 I 3 (20%) PD, 5 (33%) SD
Wagner et al, ASCO abstract 2009 Vin, Irinotecan, Temozolomide 3 5 I 1 (3%) PR,2 (6%) OR
McGregor et al, Cancer, 115 (8): 1765-75 [39] 2009 Oxaliplatin, Irinotecan 6 1 I 1 (8%) CR, 1 (8%) SD
  1. Abbreviations: ClR = Clinical Response; CR = Complete Response; Cyclo = cyclophosphamide; Doxo = doxorubicine; EFS = Event Free Survival; Etop = etoposide; Ewing = Ewing Sarcoma; Ifos = ifosfamide; No = number; OR = Objective Response; Osteo = Osteosarcoma; PD = Progressive Disease; PR = Partial Response; RR = Response Rate; SCR = Stem Cell Rescue; SD = Stabile Disease; TMR = Total Marrow Radiation; Vin = vincristine